SVB Leerink Analysts Lift Earnings Estimates for Talaris Therapeutics, Inc. (NASDAQ:TALS)

Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) – Stock analysts at SVB Leerink increased their Q2 2023 EPS estimates for Talaris Therapeutics in a research report issued to clients and investors on Tuesday, May 16th. SVB Leerink analyst M. Foroohar now expects that the company will earn ($0.15) per share for the quarter, up from their previous forecast of ($0.20). The consensus estimate for Talaris Therapeutics’ current full-year earnings is ($0.81) per share. SVB Leerink also issued estimates for Talaris Therapeutics’ Q3 2023 earnings at ($0.15) EPS, Q4 2023 earnings at ($0.17) EPS, FY2023 earnings at ($0.99) EPS and FY2024 earnings at ($0.27) EPS.

TALS has been the subject of a number of other research reports. Morgan Stanley decreased their target price on shares of Talaris Therapeutics from $6.00 to $3.00 and set an “equal weight” rating for the company in a research report on Thursday, February 23rd. HC Wainwright downgraded shares of Talaris Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, April 17th.

Talaris Therapeutics Trading Up 5.9 %

Talaris Therapeutics stock opened at $2.85 on Friday. The company has a market cap of $119.73 million, a P/E ratio of -1.72 and a beta of 2.27. Talaris Therapeutics has a 1-year low of $0.89 and a 1-year high of $9.21. The company has a fifty day simple moving average of $2.25 and a 200 day simple moving average of $1.74.

Insider Buying and Selling at Talaris Therapeutics

In other Talaris Therapeutics news, Director Suzanne Ildstad sold 21,753 shares of the stock in a transaction on Wednesday, April 19th. The shares were sold at an average price of $2.16, for a total value of $46,986.48. Following the completion of the sale, the director now owns 2,883,389 shares in the company, valued at $6,228,120.24. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 150,493 shares of company stock worth $324,488 over the last quarter. 16.60% of the stock is currently owned by insiders.

Institutional Trading of Talaris Therapeutics

Large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in shares of Talaris Therapeutics by 33.6% during the 1st quarter. JPMorgan Chase & Co. now owns 18,341 shares of the company’s stock worth $34,000 after buying an additional 4,613 shares during the last quarter. Susquehanna International Group LLP acquired a new stake in Talaris Therapeutics in the 1st quarter worth about $27,000. State Street Corp raised its stake in Talaris Therapeutics by 5.4% in the 1st quarter. State Street Corp now owns 354,729 shares of the company’s stock worth $667,000 after purchasing an additional 18,087 shares in the last quarter. Geode Capital Management LLC raised its stake in Talaris Therapeutics by 10.9% in the 1st quarter. Geode Capital Management LLC now owns 408,110 shares of the company’s stock worth $767,000 after purchasing an additional 40,190 shares in the last quarter. Finally, Deutsche Bank AG raised its stake in Talaris Therapeutics by 61.5% in the 1st quarter. Deutsche Bank AG now owns 14,154 shares of the company’s stock worth $27,000 after purchasing an additional 5,388 shares in the last quarter. Institutional investors and hedge funds own 65.43% of the company’s stock.

About Talaris Therapeutics

(Get Rating)

Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.